Pharmacy Discount Meds

Five month studies ASSOCIATED PRESS have found that small quantities medicine, including antibiotics, sexual hormones, and anti-compositions of the seizure, are discovered in public, water delivered to over 40 million American on USA.

While concentration such small they must be in a parts for billionth or even parts for trillion, and water companies persist that these level - within safe limit, AP reported that old period is produced on public health so much medicines of the prescription and on counter medicine such as, acetaminophen and ibuprofen, on small amount even, begins to disturb the scientist.

The Medicine and their derived fall into water supply of the drink since when people in medication go in toilet, they will select his(its) body does not absorb and any matabolized by-products. The Water companies address the waste before unloading this in yard, lake and reservoirs, then address this once again previously, than she will enter the water system of the drink. However, different processing do not delete all traces a medicine.

During five months, the National Investigative Group AP visitted the plants of the processing polled over 200 scientists, representatives and academician, analysed federal database and hundreds of the scientific messages.

Amongst their questions, the investigators AP came across the research studies that “will go practically unespied general public” where scientist were concerned about on effect water polluting material of the drink in human cell and alive nature.

The Investigators also found that water companies do not do to love to publish the results a medicine, fencing tests since they think that public will not want to know what interpret them and must become in vain alarmed. However, Protection Of environment Agency USA (the EPA) assistent manager for water, Benjamin H Grumbles reported by AP this:

“We shall acknowledge that this - a growing enxiety and we take this much seriously.”
USA Food and Administration Medicine of the Consulting Committee Medicine Oncologic solved to recommend the restrictions in use medicine to anemias to process the patient with certain types of the cancer.

The Medicine in question, which includes Amgen’s Aranesp and Epogen, and Johnson & Johnson’s Procrit, is named erythropoiesis agents, or ESAs and are used to raise the red blood cells on patient who usually becomes anaemic from kidney disease or chemotherapies.

The Panel voted 13 on 1 in favour of keeping medicine for use much cancerous patients, reported NEW-YORKSKOE Time.

But is voted to recommend that medicine are not used to process the patient with doggy style bosom or main and cancer to necks ( the voice was 9 on 5 in favour of restrictions). The Main and paradise to necks include that to which affects the throat, nodes of the sinuses and lymphs.

And in the one third voice, committee recommended that medicine were not used in events where intention must restore the patient cancer (11 on 2, with 1 abstention). This usually refers to patient, having chemotherapy, following surgery for early cancer of the stage, and where doctors believe there is chance cancer is removed.

Usually follows the recommendation their own consulting committee, but this no has to. The Representatives Agency reported striking, which they will consider these recommendations immediately but do not give no concrete dates for decision, reported ASSOCIATED PRESS.

John Jenkins, for new medicine have said that was clear from debate that panel was a worried safe risk ESAs, but was not determined about area of the risk. “Us have no excellent given about this point,” said Jenkins.

The Acknowledgement scanned by panel came from 8 studies on ESAs that taken as a whole to install, reminded that medicine hurried the death and tumour growing when is used to reach the level of the haemoglobin above than that were recommended on label medicine (so cancealled use the label).

Amgen And J&J reported that studies did not show the consequent sample a result brought by, and noted that studies looked at above than recommended haemoglobin takes aim.

The Companies medicine have said that they still test the medicine for level within that recommended by label but results will not be through during at least once five years.

The Committee also discussed the tactician of the sellouts was used by companies medicine, where greater discounts are given for bulk aquisition, and there is casual doctors can the profit if indemnity, they become from insurer and patients exceeds that they have paid for medicine, reported NEW-YORKSKOE Time. Some panel the participant said this called on on use medicine, companies medicine have said this no.
The Government of the Canada today declared the official opening of the Food and Medicine Act the Office a Relationship (FDALO) to be a deal with questions comparatively Food and Actions Medicine.

” New Food and Medicine Act the Office a Relationship is part of serieses of the initiatives designed to modernize and intensify the Canadian safe system for food, health and consumer products,” said Minister Soft, Minister of Health. “Like Food and Consumer Safe Plan of the Action declared in December 17, 2007, new office is also serviced to execute our Governmental obligation to perfect continuously their own mechanisms to account abilities when he comes to material referring to Food and Action Medicine.”

Asked that manufacturers Crestor ceased to publish ad targeted on patient sent the letter to Astra Zeneca in 21-y December, speaking that this was concerned about that ad to can to play well together downwards risk bound Crestor.

spokesperson For AstraZeneca reported ad was one. He has added that ad not anymore anyway. He has persisted to Crestor such safe as any other statin.

Crestor Contains the medicine rosuvastatin, which belongs to the group a medicine heard as HMG-CoA reductase inhibitors, or ’statins.

Crestor is Used to modify the emergency level fat substance on blood named lipids, mainly high level of the cholesterol and triglycerides. Crestor is Used in combinations with plan of the diet when change on diet and exercise only did not reduce the high cholesterol and triglycerides.

Rosuvastatin Belongs to the group a medicine heard as HMG-CoA reductase inhibitors, or ’statins.

– HMG-CoA reductase, - an enzyme (chemical) in tele what transformations 3-hydroxy-3-methylglutaryl coenzyme to mevalonate, which - then transformed in cholesterol.

– Brake HMG-CoA reductase, Crestor reduces the general amount of the cholesterol made by body.

– There is 2 types of the cholesterol on shelters, cholesterol LDL- (”Bad Cholesterol”) and cholesterol HDL- (”Good cholesterol”)

– Brake HMG-CoA reductase, results Crestor in more low level (”Bad”) cholesterol LDL-and reduces triglycerides on shelters.

CRESTOR ALSO on raised level (”Well”) cholesterol HDL-on shelters.

Crestor Available as as soon as day tablet, which can be given anytime day and can be will take with or without the food.

Astrazeneca Declared start the new clinical test, SATURN, designed to measure the influence CRESTOR (rosuvastatin) 40 mg. and Lipitor (atorvastatin) 80 mg. in passing on high patient of the risk. THE SATURN confer the effects these two statins on abilities to reduce the passing or generate the regression the main reason cardiovascular disease, the following two years of the processing on patient with disease of the coronary artery.

Dr George Kassianos, GP, Bracknell and Lad European Society to Cardiologies commented: ” announcement of this head main analysis between rosuvastatin and atorvastatin agitates the news to as this for the first time addresses important clinical and scientific questions by direct comparison. THE SATURN of the analysis will provide the by best understanding effect these two well installed statin processing on patient with leading and as to address them accordingly.”

THE SATURN, (the Study Coronary Atheroma Ultrasound InTravascular: Effect Rosuvastatin Against AtorvastatiN), - 104- week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) visualizing study aproximately 1,300 patients in 170 centres worldwide. The First patient will be enrolled following this month and analysis is expected terminate in 2011. THE SATURN - a part of extended clinical test the GALAXY AstraZeneca’s programme, to address the important unanswered questions in statin study and to research the influence rosuvastatin on management lipids, and heartily morbidity and mortality. Currently, more, than 63,000 patients with 55 countries worldwide to participate in Program of the GALAXY.

Elisabeth Bjork, Global Medical Director of the Science for CRESTOR commented: “Two specialize the studies in program of the GALAXY have already demonstrated the significant influence CRESTOR 40mg in through spectrum disease. The Analysis of the ASTEROID was first to show the regression coronary on patient with installed by disease, and analysis of the METEOR shown that CRESTOR can also slow or delay the passing carotid on patient with early sign disease. Results of the SATURN of the analysis will provide additional information on as to the best advantage to process patient with leading

CRESTOR has NOW got the plenipotentiary approvals in over 90 countries. Over 11 million patient, is given CRESTOR worldwide.

New given presented today in National Medical Assotiation Hispanic (NHMA) annual meeting shown that AstraZeneca’s CRESTOR(R) (rosuvastatin calcium) in 10 and 20 mg reduced LDL-C or cholesterol “bad” to 45.2 and 50.0 percent, in contrast with 35.9 and 42.4 percent with atorvastatin in dose on patient Hispanic with elevated cholesterol (p<0.017 vs of the dose atorvastatin). THE INTERSTELLAR nave (STUDY to Value Rosuvastatin in Population HIspanic), - first-ever large-scale, expected test solely designed to compare the effects statins on patient Hispanic, who usually underrepresented in clinical test.

“INTERSTELLAR nave is a first test to demonstrate vastly greater efficiency in, reducing cholesterol LDL-on patient Hispanic, used of the dose of the milligramme CRESTOR in contrast with atorvastatin,” said Dr. Ramon Lloret, leaden investigator STARSHIP and president of the Cardiovascular Centre of the South Florida in Miami. “As physician Hispanic, which processes this on traditions underserved population, I see the firsthand importance this analysis. Test the INTERSTELLAR nave presents the important possibility to demonstrate efficiency and safety statins in this population.”

THE INTERSTELLAR nave was a poles week, mixed, operated, openning-label, much-test the centre designed to value efficiency CRESTOR and atorvastatin on patient Hispanic with elevated cholesterol. After poles week dietetic lead- in, 696 adult Hispanic mainly average and high risk patient as defined managing principle NCEP ATP III, with historian of the coronary heart disease (CHD), equivalent of the risk CHD, or 10-risk vrem)g. event Framingham CHD equal or more, than 10 percents, were mixed on one of four opened labels of the processing during poles week: CRESTOR 10 or 20 mg. or atorvastatin 10 or 20 mg. The General safe experience was similar for all processing in analysis of the INTERSTELLAR nave.

Additional given with INTERSTELLAR nave demonstrated:

- General cholesterol reduction to 32.4 and 34.9 percent with CRESTOR 10 and 20 mg. in contrast with 25.6 and 30.9 percent for atorvastatin 10 and 20 mg. (p<0.017 vs of the dose atorvastatin)

- Reduction ne-hdl-C to 40.9 and 44.6 percent with CRESTOR 10 and 20 mg. in contrast with 32.6 and 39.2 percent for atorvastatin in same dosage (vs milligramme p<0.017 of the dose atorvastatin)

- Increase HDL-C to 5.5 and 5.7 percent with CRESTOR in 10 and 20 mg. in contrast with 3.5 and 4.3 percent with atorvastatin in dose

These given also were recently presented in American College of the Cardiologies (ACC) of the annual meeting. Under-analysis with INTERSTELLAR nave, in reactive protein C- (CRP) was recently submitted for 46-y Annual Conference in Cardiovascular Epidemoloshii Disease and Preventions with Advice in Feeding, Physical Activity, and Metabolism subsidized the American Warmhearted Assotiation and found that CRESTOR reduced the level CRP from baseline. These results shown 18.8 and 26.7 percent of the reduction on level median CRP with CRESTOR 10 and 20 mg. in contrast with 16.8 and 23.8 percent of the reduction with atorvastatin in dose milligramme (vs. the baseline p<0.01). CRP - a protein in tele, which - not-specific marker of the inflammation.

The Primary endpoint of the analysis was a comparison for four weeks patient, which reached target diastolic blood pressure (the feeding trough, sitting DBP <90 mmHg) on HYZAAR 50-12.5 mg. against patient on COZAAR (losartan tablets potassium) 50 mg titrated on 100 mg. as needed to reach target diastolic blood pressure. The Results learns at week four shown:

– Average reduction in diastolic pressure was 13.6 mmHg for patient, HYZAAR vs. 10.5 mmHg during that taking COZAAR, difference 3.1 reduce mmHg for that addressed HYZAAR.

– Average reduction in systolic pressure was 18.0 mmHg during that taking HYZAAR vs. 12.4 mmHg for on COZAAR, difference 5.6 mmHg for that addressed HYZAAR.

As a result, big proportion patient on HYZAAR reached target diastolic blood pressure (17.6 percent for HYZAAR, 9.4 percent for COZAAR; p=0.006). The Similar directions were seen when patients were grouped according to sort, racing or age (less than 65 and 65 or more old).

The Secondary endpoint was a comparison on poles week patient, which reached target diastolic blood pressure in HYZAAR 50-12.5 mg titrated as needed HYZAAR 100-25 vs patient mg. in mg COZAAR 50 titrated on 100 mg. and then in 150 mg. The Results learns at week poles shown:

– Average reduction in diastolic pressure was 17.8 mmHg for patient, HYZAAR vs. 11.9 mmHg during that taking COZAAR.

– Average reduction in systolic pressure was 25.1 mmHg during that taking HYZAAR vs. 14.1 mmHg for on COZAAR.

On poles week, more patient HYZAAR target diastolic blood pressure addressed in group than that addressed COZAAR (29.8 percent 12.5 percent vs.).

“In clinical analysis, supporting this new instruction, we saw that more patient with serious hypertension their diastolic blood pressure, reducing purpose less than 90 mmHg for four weeks with HYZAAR in contrast with titrated in more high doses COZAAR,” said Dr. Bakris.

In clinical test, the processing with HYZAAR usually was well tolerated. In clinical analysis, supporting this new instruction, the general profile of the side effect for patient with serious hypertension addressed HYZAAR as initial therapy was like profile of the side effect on patient with serious hypertension addressed COZAAR as initial therapy. For period of the analysis was not no registered events of the syncope in any group of the processing. There were two events (0.6 percent) and no events hypotension registered in group addressed HYZAAR and COZAAR, accordingly. There were three events (0.8 percent) and two events (1.2 percent) raised wheys creatinine (> 0.5 mg./dl) in group addressed HYZAAR and COZAAR, accordingly.

In other clinical test, the general incidence disadvantage event with losartan kaliem-hydrochlorothiazide was comparable to Most general disadvantage events, coming of different dose losartan kaliya-hydrochlorothiazide (n=858) at a rate of one percent or more said (n=173) were an upper infection respiratory (6 percents 5 percents vs.), dizziness (6 percents 3 percents vs.), pain (2 percents vs. 1 percent), thrill (1 percent vs. 0 percents) and rash (1 percent vs. 0 percents).

When is used in pregnancy during the second or the third trimester, medicine, which act right in renin-system angiotensin can cause the damage and even death in devising fetus. When pregnancy is discovered, COZAAR and HYZAAR must stop at earliest convenience.

COZAAR And HYZAAR contraindicated on patient, which supersensitive in any component of these products. Because of component hydrochlorothiazide, HYZAAR also contraindicated on patient with anuria (the absence of the forming the urine) or hypersensitivity in other sulfonamide- derived medicine. HYZAAR is NOT recommended for patient with serious kidney deterioration (creatinine clearance = 30mL/min) or as facility titration for patient with liver deterioration. HYZAAR is NOT recommended for use as initial therapy on patient with intravascular volume depletion (eg., that addressed by diuretics). All patients, getting thiazides must be for clinical sign fluid or imbalance of the electrolyte, including hypokalemia. Either as the other medicine, which block angiotensin II or effects, use the concomitant potassium-moderate diuretics, additions potassium, or salty change, containing potassium can conduct to increase in potassium of the whey.

Starting dose HYZAAR for initial processing the serious hypertension - one tablet HYZAAR 50-12.5 mg. as soon as daily. For patient who does not acceptable on HYZAAR 50-12.5 mg. after two for four weeks therapy, dosage can be increased in one tablet HYZAAR 100-25 mg. as soon as daily. The Maximum dose is one tablet HYZAAR 100-25 mg. as soon as daily. HYZAAR is NOT recommended as initial therapy on patient with liver deterioration since approaching 25 mg. starting dose losartan not to can to be given.

Usually starting dose COZAAR on patient with hypertension - COZAAR 50 mg. as soon as daily. The Maximum daily dose - 100 mg. If effect antihypertensive measured in use the feeding trough as toliko-a-day dosing will be inadequate, dvazhdy-a-day mode in same general daily dose or increase in dose can give the more satisfactory answer. 150 Mg. doses COZAAR are not shown to give the better performance than 50 mg. or 100 mg. On patient, which - a volume-exhausted, symptomatic hypotension to can to occur after initiation therapy with COZAAR. This condition must be updated before administration COZAAR, or dosage COZAAR 25 mg. must be used. On patient with historian of the liver deterioration, starting dose COZAAR 25 mg. must be used.

The Patients, whose blood pressure did not finish monotherapy with COZAAR or hydrochlorothiazide only can be switched to HYZAAR 50-12.5 mg. as soon as daily. If blood pressure remains uncontrolled, physicians can titrate on HYZAAR 100-25 mg. as soon as daily.

Chosen important information on HYZAAR and COZAAR When is used in pregnancy during the second or the third trimester, medicine, which act right in renin-system angiotensin can cause the damage and even death in devising fetus. When pregnancy is discovered, COZAAR and HYZAAR must stop at earliest convenience.

COZAAR And HYZAAR contraindicated on patient, which supersensitive in any component of these products. Because of component hydrochlorothiazide, HYZAAR also contraindicated on patient with anuria (the absence of the forming the urine) or hypersensitivity in other sulfonamide- derived medicine.

HYZAAR is NOT recommended for patient with serious kidney deterioration (creatinine clearance <30mL/min). HYZAAR is NOT recommended for titration for patient with liver deterioration since approaching 25 mg. starting dose COZAAR not to can to be given. On patient, which exhausted volume (eg., that addressed by diuretics), symptomatic hypotension to can to occur after initiation therapy with HYZAAR. This condition must be updated before administration HYZAAR. All patients, getting thiazides must be for clinical sign fluid or imbalance of the electrolyte, including hypokalemia.

On patient, which - a volume-exhausted, symptomatic hypotension to can to occur after initiation therapy with COZAAR. This condition must be updated before administration COZAAR, or dosage COZAAR 25 mg. must be used. On patient with historian of the liver deterioration, starting dose COZAAR 25 mg. must be used. Either as the other medicine, which block angiotensin II or effects, use the concomitant potassium-moderate diuretics, additions potassium, or salty change, containing potassium can conduct to increase in potassium of the whey.

In other clinical test with losartan for hypertension, most general disadvantage events with incidence greater or equal two percents patient addressed COZAAR (n=1,075) and occurring more usually than (n=334) included upper infection respiratory (8 percents for losartan 7 percents vs for dizziness (3 percents for losartan 2 percents vs for nose overloading (2 percents for losartan vs. 1 percent for and inverse pain (2 percents for losartan vs. 1 percent for.

In other clinical test with losartan kaliem-hydrochlorothiazide, the general incidence disadvantage event was comparable to Most general disadvantage events, coming of different dose losartan kaliya-hydrochlorothiazide (n=858) at a rate of one percent or more said (n=173) were an upper infection respiratory (6.1 percent 4.6 percent vs.), dizziness (5.7 percent 2.9 percent vs.), cough (2.6 percent 2.3 percent vs.), pain (2.1 percent 0.6 percent vs.), thrill (1.4 percent vs. 0 percents) and rash (1.4 percent vs. 0 percents).

In clinical analysis, supporting initial therapy instruction, the general profile of the side effect for patient with serious hypertension addressed HYZAAR as initial therapy was like profile of the side effect on patient with serious hypertension addressed COZAAR as initial therapy. For period of the analysis was not no registered events of the syncope in any group of the processing. There were two events (0.6 percent) and no events hypotension registered in group addressed HYZAAR and COZAAR, accordingly. There were three events (0.8 percent) and two events (1.2 percent) raised wheys creatinine (> 0.5 mg./dl) in group addressed HYZAAR and COZAAR, accordingly, during the same length of time.

The School District of Palm Beach County in Florida plans to begin a new sex education curriculum in April that will teach sixth-grade students about contraception and teach seventh-grade students how to use condoms, the Palm Beach Post reports.

The new curriculum is a response to concerns from Palm Beach County Health Department officials that existing sex education classes for elementary and middle school students did not provide enough information on preventing pregnancy or sexually transmitted infections. The old curriculum taught sixth graders about STIs and how to resist pressure to have sex but had few details about STIs and did not mention condoms, Viagra pills the Post reports. Jean Malecki, the health department’s director, began criticizing the old curriculum about one year ago.

Sex education for middle school students in the district will change the most under the new curriculum, according to the Post. Comprehensive sex education will be added to elementary grades, but the lessons will focus on self-esteem, respect and character.

The classes will be taught mainly by science teachers in the district’s middle and high schools. Superintendent Art Johnson has said science teachers might not be well-suited or have the expertise to teach sex education. The district is requiring that teachers attend five training sessions before teaching the lessons. The district also has developed a PowerPoint presentation to be used during the lessons to ensure the material is consistent and to serve as a syllabus for parents.

According to the Post, there has not been significant opposition to the new curriculum. Judy Klinek, who oversees health education for the district, said students need to receive sex education before they are teenagers. Marsha Fishbane, director of school health for the health department, said that the district’s old sex education curriculum was “just beginning to scratch the surface” of pregnancy and STI prevention.

State Sen. Ted Deutch (D) is sponsoring a measure (SB 848) that would require public schools in the state that receive state funding for sex education buy Viagra online to provide a comprehensive curriculum. Deutch has cited studies that found many parents and teachers did not believe sex education programs in the state were effective at helping teenagers prevent pregnancy and STIs.

Florida has the sixth-highest teen pregnancy rate nationwide, the Post reports. A 2005 Florida Youth Risk Behavior Survey found that about 50% of high school students in the state have had sex, including some before age 13 (DeNardo, Palm Beach Post, 2/14).

Reprinted with kind permission from Buy Viagra. You can view the entire Daily Women’s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women’s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

Did you know that common health problems can be associated with your sex life? Diabetes, depression and hypertension are just some of these. All recent data prove that a healthy sex life can indicate general well-being. And do we want to find out more? Do we consider it as one of our problems? The European Sexual Dysfunction Alliance (ESDA) wants to remind everyone of the importance of sexual health as a part of overall health and show what as an alliance we have just found out!
Buy Levitra in Online Pharmacy.
What Is ESDA?

ESDA is an umbrella organisation for patient support help-lines across Europe. These organizations exist to provide sufferers and their partners with information and support on issues of sexual health through telephone help-lines, by email and post. They have national websites and fact sheets on different sexual problems in different languages and these can be sent to callers who request them free of charge.

ESDA has been holding an awareness campaign around St Valentine’s Day since 2003 with the aim of drawing attention to the sexual health problems of many men and women in Europe. The event is supported by The European Society for Sexual Medicine (ESSM) and concludes on or around the 14th February in all participating countries simultaneously.

This year all countries participating at this alliance through their national centres, we want to stress the importance of consulting sexual problems with the health care provider as in many cases these difficulties can be the first sign of a serious underlying health condition which has gone undetected and undiagnosed.

Presenting Our European Data

Recent data from just some of the ESDA help lines shows just how common these problems really are. ESDA help lines in France, Greece, UK, Spain and Sweden received a total of 11.000 calls during last year. The largest number of calls was received in countries with the higher numbers of population of course. In France only, over 4500 people were seeking help as well as in UK with over 3000 phone calls.

Men or Women?

Men can hide. Perhaps that is the reason that throughout the continent, men were asking help from the national help-lines, no matter if they are living in Mediterranean or in the north of Europe. In France male callers represented 92, 6, in Sweden 71%, in Spain 93%, in Greece 88.5% and in the UK 75% of all calls were from men.

Has asking about sexual health to do with age?

The ages of the callers ranged from 16 to 87 years with an average age of 48 in the UK, 50 in France, 43 in Greece and 46 in Spain. The majority of callers were in stable relationships: 45% in Greece, 82% in France and 87% in Spain.

But what Europeans are doing for their sexual health?

Unfortunately, very few! Most interestingly the majority of callers to all national centers, both male and female had never consulted a health professional about their sexual problem: 75% of male callers in Sweden, 70% in Greece, 64% in France and 55% in Spain. In the case of women, still not a lot were trying to find a specialist to consult regarding sexual issues: 55% in Sweden, 60 in Greece, 64% in Spain, and 71% in France had never consulted their problem. This is particularly surprising when you look at the amount of time they had had the problem. In France men had suffered a sexual dysfunction for 3 years on average before calling the helpline and women just over 3 years, whereas in Greece and Spain men had waited over 4 years and women in Spain almost 5 years before calling for help.

What do Europeans report regarding their sexual life to a help-line?

Regarding the type of sexual problem consulted ESDA data shows that in all countries men called primarily for erectile dysfunction (ED), 75% in France, 72% in Greece, 65% in Spain, 55% in Sweden and 58% in the UK. But in the era of the drugs trying to help people with ED, still there is the problem with premature ejaculation: the second most consulted problem by men calling the help lines, with 19% in Greece, 25% UK, 12% in Spain and 10% in Sweden. What about women? Of all calls received in Greece, 11.5% were from women. In their case the most common problem was decreased sexual interest and desire: 30% in Sweden, 45% in Greece, 37% in France and 50% in the UK. And as expected their second most common reported dysfunction was orgasmic dysfunction, 36% in Greece, about 11% in Sweden and France and 8% in Spain.

Sexual health: related to the overall health of men?

Some of the most interesting data emerges when one looks at concomitant diseases: In Greece approximately 20% of men had cardiovascular disease, followed by 11% diabetes and 3% prostate. In Spain nearly 31% of men had cardiovascular disease followed by 16% prostate problems and 15% diabetes mellitus. In the UK however 12% of male callers claimed they suffered from depression/anxiety and 10% had diabetes. Data from Sweden show that 6% of the men who called the helpline had cardiovascular disease, 6% had a concomitant psychiatric disease and 4% diabetes. In France 20% had cardiovascular problems, 12% had diabetes and as for prostate problems, 7.4%.

What about the underlying conditions reported by women calling the help-lines?
Online Pharmacy: Viagra, Cialis, Levitra, Kamagra and Tramadol (ultram), Soma….
There were some important differences seen in different European countries. When presenting national data it was found that in Spain and Greece psychiatric/psychological problems were reported by 14% and 11% of women callers respectively. In Sweden the most common associated problems were gastrointestinal 8%, 6% osteoporosis and 4% cardiovascular disease. The most common medical problem reported by women in France was cardiovascular (17%) followed by psychiatric/psychological problems (25%), 13% lifestyle and 10% diabetes.

ESDA provides sufferers, their partners and the general public with information about their problem and guides them on their way to finding a solution. We also offer support and reassurance. Men and women can call the helpline anonymously in their country and a telephone advisor will discuss the problem with them in a natural and relaxed manner and encourage them to consult their doctor. They can be sure they are not alone: prevalence studies show that, sexual health problems are very common, are often ignored leading to a negative impact on a person’s quality of life, their personal relationships and their self-esteem. Additionally it is vital for the public to know that they are often the first sign of an important undiagnosed heath problem such as diabetes, hypertension, depression and others.

A visit to the doctor to discuss the problem is crucial as the first step to getting the right assessment, tests, treatment and follow up. We would also like to stress that any medication purchased on the Internet without a proper guarantee and taken without medical supervision can be dangerous and should be avoided in the interests of safety.

Tags: health, Pharmacy Online, Men’s health, Med, Smoking, Drug, Sexual Health, Medical Online, Urology, Disease, SMOKING, Order Tramadol Online, sexual men’s health, drugs, diabetes, asthma, laboratory, Buy Levitra Online

Nine out of ten doctors have no confidence in the government’s ability to safeguard patient data online, a poll conducted by BMA News has revealed.

More than 90 per cent of respondents (93 per cent) to the survey said they were not confident patient data on the proposed NHS centralised database would be secure.

A series of recent high-profile data losses, such as the HM Revenue and Customs computer discs containing the details of 25 million child benefit claimants and security breaches during last year’s online training recruitment fiasco for junior doctors, have left doctors sceptical about safety.

Nine out of ten of the 219 doctors who responded to the Doctors Decide poll said they did not feel they were in a position to assure patients that their data would be safe.

More than eight out of ten (81 per cent) said they would not want their surgery data stored on the national NHS ’spine’.

Wiltshire trainee cardiologist Dr Sally Simmons was one of those caught up in the medical training application service security breaches last year. Her personal details became publicly available and could potentially have been used by identity thieves.

She said: ‘I have received no apology from the Department of Health despite writing to the former health secretary [Patricia Hewitt]. I was also affected by the loss of the two child benefit CDs with my bank details on them. Not surprisingly, I have no faith in any form of IT security that this government proposes.’

However, Berkshire GP and consultant in family planning Dr Meg Thomas said: ‘This will help with continuity of care and communication between primary and secondary care … There may be a risk but paper records are also going astray. We need to join the 21st century and quick.’

Full text of BMA News Doctors Decide story follows in full:

Do you have confidence in the government’s ability to safeguard patient information on a national NHS database?
6% said Yes
93% said No

Here are some of your thoughts

No: ‘I was one of the final-year medical students affected by the online MTAS (medical training application service) details being available to identity fraudsters. I have received no apology from the Department of Health despite writing to former health secretary Patricia Hewitt. I was also affected by the loss of the two child benefit CDs. Not surprisingly, I have no faith in any form of IT security that this government proposes.’

No: ‘With the MTAS debacle, the government has proven itself to be pretty incompetent in handling and protecting sensitive data. Forget ID cards; the national NHS database poses an even greater risk of our personal data being released into the public domain and being misused.’

No: ‘MTAS. Need we say more?’

Yes: ‘Many institutions, including banks, have done it. So why should the NHS lag behind? Protecting data would always be challenging, but it should not prevent patients and doctors from reaping the benefits of an easily accessible database.’

No: ‘With the government’s recent underhand dealing with regard to general medical services contracts and the contracts of staff and associate specialist doctors, we might wonder whether it would have other uses for the information that might not be in patients’ best interests. Previous government guarantees of security have not been worth the paper they were written on.’

Do you feel you are in a position to assure patients that their data will be safe?
4% said Yes
90% said No

Here are some of your thoughts

No: ‘A better and cheaper solution would be for patients to carry and be responsible for their own medical information, using a portable database in card or stick format. Only patients with multiple pathologies or complex medical needs would need to be supplied with this information. It could be easily transported as a necklace pendant or bracelet similar to the medic-alert style of personal jewellery.’

No: ‘A central database with details of past medical history, current medications and allergies would be very helpful when managing patients from out of town in emergency departments. But the recent debacles in data management make it very difficult to convince patients to give consent for uploading their medical histories onto a central system with which the security of data could not be guaranteed 100 per cent.’

Yes: ‘This will help with continuity of care and communication between primary and secondary care … There may be a risk, but paper records are also going astray. We need to join the 21st century and fast.’

No: ‘The BMA should immediately take out full-page advertisements in the national press informing patients that their health records are about to be placed on an unsafe system. The adverts should provide a cut-out form that patients can give to their GPs to opt out of this dangerous and inadequately secured system.’

Would you want your own data stored in this way?
9% said Yes
81% said No

Here are some of your thoughts

No: ‘I have already asked my own GP practice to code my records in a way that will hopefully prevent an upload on to the central database. ‘I hope that the BMA will now provide leadership on this issue to prevent the government putting the confidentiality of patient medical records at such risk. It should call for the care record service to be abandoned.’

Yes: ‘I think it is important to put this in the context of the information that we share every day through online shopping, joining websites and social networking websites such as Facebook. It is interesting to reflect on the amount of information that is in the public domain already, such as the information used by supermarkets about your shopping habits. ‘The essence of Connecting for Health is improving the patient experience and reducing workload for doctors by reducing repetition … Concerns are valid, but because of those concerns and the clinicians involved this is likely to be the most secure database. Let us start discussing its benefits and stop bashing its potential flaws.’

No: ‘I live in Bolton [where electronic records are being piloted] and have opted out. Even if the data were safe and the system worked, it would never provide value for money.’

No: ‘I have already emailed chief medical officer for England Professor Sir Liam Donaldson to say that I am exercising my choice as a patient and do not want my details on any national database. I got the usual bland non-committal reply.

‘I do not mind my GP knowing about my medical history, and if I moved around the country while on holiday, for example, I would be happy to answer questions posed by any GP or hospital doctor if I was taken ill.’

Yes: ‘With patients being treated in multiple sites by numerous professionals, there is no way we can go on as we are - struggling to collect all relevant data and constantly repeating data collection and rewriting data. We must have IT and share data, even if there are risks.’
Source: http://www.medicalnewstoday.com/articles/96079.php

NanoBio Corporation is presenting safety and efficacy results on new topical treatments for herpes labialis (cold sores) and onychomycosis (toe nail fungus) at the annual meeting of the American Academy of Dermatology (AAD), being held February 1-5, 2008, in San Antonio.

The data being presented indicate that the company’s topical lotions, composed of nanometer-sized droplets, have potent antiviral and antifungal effects without safety concerns or systemic absorption. Interim findings in subjects with cold sores demonstrate faster healing without skin irritation or safety concerns. Initial results in subjects with toe nail fungus indicate an excellent safety profile with no systemic absorption coupled with an ability to kill the fungi that cause onychomycosis, a common condition affecting up to 36 million people.

“We are very encouraged by our preliminary results,” said James R. Baker Jr., M.D., founder and chairman of NanoBio Corporation. “Our human and animal studies show that NanoBio’s products are well tolerated and without safety issues, adverse events or skin irritation concerns. Pharmacokinetic studies show no systemic absorption, a factor that enhances the safety profile.”

Final results from a prior phase 2A study in herpes labialis, as well as interim findings from an ongoing phase 2B study, indicate a significant improvement in time to healing for subjects treated with NanoBio’s antiviral product, NB-001.

Results from a phase 1 study in onychomycosis, as well as preclinical data being presented at the meeting, indicate that NanoBio’s antifungal product, NB-002, can be safely applied to the skin at doses more than 1,000 times higher than the minimum concentration required to kill fungi.

“NB-002 exerts its effect locally by penetrating the skin and diffusing laterally underneath the nail plate to reach the dermatophytes and kill both active hyphae and spores — without irritating the epithelium or being systemically absorbed,” Baker said. “The absence of systemic involvement could provide a significant advance for onychomycosis therapy in terms of safety.” Current oral (systemic) drugs for onychomycosis pose risks of hepatic and cardiac toxicity, as well as the potential for drug interactions, Baker added.

In addition to its safety and tolerability, NB-002 activity was documented against numerous fungi involved in cutaneous infections, including Candida albicans, Microsporum canis, Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum.

NanoBio is currently conducting a double-blind, placebo-controlled, phase 2 study to further investigate the efficacy and safety of NB-002 in 443 subjects with onychomycosis. All subjects have been enrolled, and the study is expected to be completed in February 2009.

The company’s topical treatments are based on a novel anti-infective platform comprising an oil-in-water emulsion and a surfactant. The nanodroplets readily penetrate hair follicles and skin pores to reach the site of infection without disrupting skin or mucous membranes. Upon contact with the pathogen, the nanodroplets directly interact with the pathogen’s outer membranes to lyse the virus, fungus or bacteria.

Poster Titles — Link to posters at http://www.nanobio.com

– Safety, Tolerance, Pharmacokinetics, and Efficacy of Topical Nanoemulsion NB-001 for the Treatment of Herpes Labialis

– Development of a Novel Antiviral Drug (NB-001) for Topical Application in Humans

– Safety, Tolerance, and Pharmacokinetics of Topical -- Development of a Novel Antifungal Drug (NB-002) for Topical Application in Humans

Women from three low-income communities in Manila, Philippines, on Wednesday asked an appeals court to revoke a local law that bans city clinics from providing contraceptives, Reuters UK reports. Lawyers representing the women said the law is unconstitutional (Mogato, Reuters UK, 1/30).

Family planning advocates in the Philippines in September 2007 announced plans to file a lawsuit against Environment Secretary Lito Atienza for removing all contraceptives from city clinics when he was mayor of Manila. The Reproductive Health, Rights and Ethics Centre and other groups said they had testimony on how Atienza, a devout Catholic, introduced a policy in 2000 prohibiting public clinics from issuing contraceptives or educating people about how to use or obtain them. The suit aims to “hold (Atienza) liable for acts which caused injury to women,” Elizabeth Pangalangan — executive director of the Reproductive Health, Rights and Ethics Centre — has said (Daily Women’s Health Policy Report, 10/2/07).

Sylvia Estrada Claudio, a doctor and head of a local nongovernmental organization helping the women, said it took eight years to seek a court order to revoke the local law because women were afraid to testify. “We have a new mayor who has a more open mind [on] other forms of family planning methods,” she said, adding that she is optimistic that the ban will be revoked. Gerry Cruz, a doctor and member of the Philippine Family Planning Organization, said, “We’re supporting these women’s petition not just from the legal point of view, but more on the health aspects because we saw a study showing an alarming increase in maternal deaths in Manila due to multiple pregnancies,” Cruz said.

According to Reuters, higher-income residents in the Philippines have been able to access prescription contraceptives in private clinics, but lower-income residents have largely depended on USAID, which has been the largest supplier of contraceptives in the Philippines for the last 30 years. However, USAID has begun to phase out its program and plans to end donations in 2008. Cruz said the country’s population could reach 150 million in the next 20 years if the government does not develop an effective population management program. According to Reuters UK, about 500,000 women annually are estimated to have abortions in the country despite the procedure being illegal, and many of them die because the practice is performed by untrained people (Reuters UK, 1/30).

Reprinted with kind permission from http://blog.pharmacydiscountmeds.com/. You can view the entire Daily Women’s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women’s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.